publication . Article . 2018

Dengue, zika, chikungunya and the development of vaccines

Isabel N. Kantor;
Open Access English
  • Published: 01 Jan 2018 Journal: Medicina (Buenos Aires), volume 78, issue 1, pages 23-28 (issn: 0025-7680, eissn: 1669-9106, Copyright policy)
  • Publisher: Fundación Revista Medicina
Dengue (DENV), zika (ZIKV) and chikungunya (CHIKV), three arbovirosis transmitted by Aedes mosquitoes, have spread in recent decades in humid tropical and subtropical zones. Dengue is epidemic in subtropical areas of Argentina. DENV infection confers lasting immunity against the infecting serotype but increases the risk of serious disease upon reinfection by any of the other three. The recombinant tetravalent vaccine Dengvaxia® prevents severe dengue and hospitalization in seropositive subjects. In 2017, Dengvaxia was approved in Argentina, for ages 9 to 45, but is not included in the national vaccination calendar. Two other vaccines are in Phase III evaluation:...
Medical Subject Headings: virus diseases
free text keywords: arbovirus, dengue, zika, chikungunya, vaccine development, Argentina, lcsh:Medicine, lcsh:R, lcsh:Immunologic diseases. Allergy, lcsh:RC581-607, lcsh:Infectious and parasitic diseases, lcsh:RC109-216
Download from
38 references, page 1 of 3

5. Lucchese G, Kanduc D. Zika virus and autoimmunity: From microcephaly to Guillain-Barré syndrome, and beyond. See comment in PubMed Commons belowAutoimmun Rev 2016; 15: 801-8. [OpenAIRE]

6. Panchaud A, Stojanov M, Ammerdorffer A, Vouga M, Baud D. Emerging role of Zika virus in adverse fetal and neonatal outcomes. Clin Microbiol Rev 2016; 29: 659-94. [OpenAIRE]

7. OMS. Chikungunya. Nota descriptiva. Abril 2017. En: http://; consultado diciembre 2017

8. Yactayo S, Staples JE, Millot V, Cibrelus L, Ramón-Pardo P. Epidemiology of Chikungunya in the Americas. J Inf Dis 2016; 214 (S5): S441-5.

9. Ministerio de Salud. Dirección Nacional de Epidemiología. Boletín Integrado de Vigilancia No. 390, SE 50, 2017. En:; consultado diciembre 2017

10. Secretaria de Vigilância em Saúde. Ministério da Saúde. Boletim Epidemiológico, Volume 48 N° 26, 2017. En: agosto/23/2017_024-Monitoramento-dos-casos-de-dengue-febre-de-chikungunya.pdf; consultado diciembre 2017.

11. PAHO/WHO. Dengue, 2017. En: index.php?option=com_docman&task=doc_view&gid=42 728&Itemid=270&lang=en; consultado diciembre 2017

12. WHO. Dengue control, 2017. En:; consultado diciembre 2017.

13. Dengue vaccine: WHO position paper. Weekly Epid Record 2016; 91: 349-64. En:; consultado diciembre 2017.

14. Wider-Smith A, Yoon IK. Edging closer towards the goal of a dengue vaccine (Editorial). Expert Rev Vaccines 2016; 15: 433-5. [OpenAIRE]

15. OMS. Inmunización, vacunas y productos biológicos. Preguntas y respuestas sobre las vacunas contra el dengue, 2017. En:; consultado diciembre 2017.

16. NIH/NIAID News Releases. Dengue vaccine enters phase 3 trial in Brazil. Jan 14, 2016. En: news-events/news-releases/dengue-vaccine-entersphase-3-trial-brazil; consultado diciembre 2017.

17. Saenz-Llorens X, Tricou V, Yu D, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. The Lancet Infect Dis 2017. DOI: [OpenAIRE]

18. Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011; 364: 1326-33.

19. Gailhardou S, Skipetrova A, Dayan GH, et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: Pooled analysis of data from 18 clinical trials. PLoS Negl Trop Dis 2016; 10(7): e0004821 [OpenAIRE]

38 references, page 1 of 3
Any information missing or wrong?Report an Issue